{"id":"https://openalex.org/W2109655434","doi":"https://doi.org/10.1136/annrheumdis-2011-200956","title":"Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160","display_name":"Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160","publication_year":2012,"publication_date":"2012-03-30","ids":{"openalex":"https://openalex.org/W2109655434","doi":"https://doi.org/10.1136/annrheumdis-2011-200956","mag":"2109655434","pmid":"https://pubmed.ncbi.nlm.nih.gov/22459542","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/3439650"},"language":"en","primary_location":{"id":"doi:10.1136/annrheumdis-2011-200956","doi":"https://doi.org/10.1136/annrheumdis-2011-200956","is_oa":true,"landing_page_url":"https://doi.org/10.1136/annrheumdis-2011-200956","pdf_url":"https://ard.bmj.com/content/annrheumdis/71/10/1671.full.pdf","source":{"id":"https://openalex.org/S25650217","display_name":"Annals of the Rheumatic Diseases","issn_l":"0003-4967","issn":["0003-4967","1468-2060"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of the Rheumatic Diseases","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://ard.bmj.com/content/annrheumdis/71/10/1671.full.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5111657027","display_name":"Josef S Smolen","orcid":"https://orcid.org/0000-0002-8899-9087","observed_orcids":["https://orcid.org/0000-0002-8899-9087"]},"institutions":[{"id":"https://openalex.org/I76134821","display_name":"Medical University of Vienna","ror":"https://ror.org/05n3x4p02","country_code":"AT","type":"education","lineage":["https://openalex.org/I76134821"]}],"countries":["AT"],"is_corresponding":true,"raw_author_name":"Josef S Smolen","raw_affiliation_strings":["Correspondence to Josef S Smolen, Medical University of Vienna, Department of Rheumatology, Vienna, Austria. josef.smolen@wienkav.at","Correspondence to Josef S Smolen, Medical University of Vienna, Department of Rheumatology, Vienna, Austria"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Correspondence to Josef S Smolen, Medical University of Vienna, Department of Rheumatology, Vienna, Austria. josef.smolen@wienkav.at","institution_ids":["https://openalex.org/I76134821"]},{"raw_affiliation_string":"Correspondence to Josef S Smolen, Medical University of Vienna, Department of Rheumatology, Vienna, Austria","institution_ids":["https://openalex.org/I76134821"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028063859","display_name":"Jonathan Kay","orcid":"https://orcid.org/0000-0002-8970-4260","observed_orcids":["https://orcid.org/0000-0002-8970-4260"]},"institutions":[{"id":"https://openalex.org/I4210162397","display_name":"UMass Memorial Medical Center","ror":"https://ror.org/053v00853","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1303243448","https://openalex.org/I166722992","https://openalex.org/I4210162397"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jonathan Kay","raw_affiliation_strings":["Department of Medicine, UMass Memorial Medical Center, Worcester, Massachusetts, USA","2Department of Medicine, UMass Memorial Medical Center, Worcester, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, UMass Memorial Medical Center, Worcester, Massachusetts, USA","institution_ids":["https://openalex.org/I4210162397"]},{"raw_affiliation_string":"2Department of Medicine, UMass Memorial Medical Center, Worcester, Massachusetts, USA","institution_ids":["https://openalex.org/I4210162397"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000282057","display_name":"Robert Landew\u00e9","orcid":"https://orcid.org/0000-0002-0577-6620","observed_orcids":["https://orcid.org/0000-0002-0577-6620"]},"institutions":[{"id":"https://openalex.org/I865915315","display_name":"Vrije Universiteit Amsterdam","ror":"https://ror.org/008xxew50","country_code":"NL","type":"education","lineage":["https://openalex.org/I865915315"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Robert B M Landew\u00e9","raw_affiliation_strings":["Department of Rheumatology, AVU Amsterdam, Amsterdam, Netherlands","3Department of Rheumatology, AVU Amsterdam, Amsterdam, Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Rheumatology, AVU Amsterdam, Amsterdam, Netherlands","institution_ids":["https://openalex.org/I865915315"]},{"raw_affiliation_string":"3Department of Rheumatology, AVU Amsterdam, Amsterdam, Netherlands","institution_ids":["https://openalex.org/I865915315"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052273654","display_name":"Eric L. Matteson","orcid":"https://orcid.org/0000-0002-9866-0124","observed_orcids":["https://orcid.org/0000-0002-9866-0124"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Eric L Matteson","raw_affiliation_strings":["Department of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA","4Department of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA","institution_ids":["https://openalex.org/I1330342723"]},{"raw_affiliation_string":"4Department of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055224792","display_name":"NORMAN B. GAYLIS","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210095528","display_name":"Arthritis and Rheumatic Disease Specialties","ror":"https://ror.org/00n3baz54","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210095528"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Norman Gaylis","raw_affiliation_strings":["Department of Arthritis and Rheumatic Disease Specialties, Aventura, Florida, USA","5Department of Arthritis and Rheumatic Disease Specialties, Aventura, Florida, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Arthritis and Rheumatic Disease Specialties, Aventura, Florida, USA","institution_ids":["https://openalex.org/I4210095528"]},{"raw_affiliation_string":"5Department of Arthritis and Rheumatic Disease Specialties, Aventura, Florida, USA","institution_ids":["https://openalex.org/I4210095528"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112722772","display_name":"J\u00fcrgen Wollenhaupt","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210101674","display_name":"Sch\u00f6n Klinik Hamburg Eilbek","ror":"https://ror.org/00pz61m54","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210088209","https://openalex.org/I4210101674"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Jurgen Wollenhaupt","raw_affiliation_strings":["Department of Rheumatology, Klinik Eibek, Hamburg, Germany","6Department of Rheumatology, Klinik Eibek, Hamburg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Rheumatology, Klinik Eibek, Hamburg, Germany","institution_ids":["https://openalex.org/I4210101674"]},{"raw_affiliation_string":"6Department of Rheumatology, Klinik Eibek, Hamburg, Germany","institution_ids":["https://openalex.org/I4210101674"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028490996","display_name":"Frederick T. Murphy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210112965","display_name":"Altoona Center for Clinical Research","ror":"https://ror.org/022q8ez38","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210112965"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Frederick T Murphy","raw_affiliation_strings":["Department of Rheumatology, Altoona Center of Clinical Research, Duncansville, Pennsylvania, USA","7Department of Rheumatology, Altoona Center of Clinical Research, Duncansville, Pennsylvania, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Rheumatology, Altoona Center of Clinical Research, Duncansville, Pennsylvania, USA","institution_ids":["https://openalex.org/I4210112965"]},{"raw_affiliation_string":"7Department of Rheumatology, Altoona Center of Clinical Research, Duncansville, Pennsylvania, USA","institution_ids":["https://openalex.org/I4210112965"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025049914","display_name":"Yiying Zhou","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yiying Zhou","raw_affiliation_strings":["Department of Biostatistics, Janssen Research & Development, LLC, Spring House, Pennsylvania, USA","8Department of Biostatistics, Janssen Research & Development, LLC, Spring House, Pennsylvania, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biostatistics, Janssen Research & Development, LLC, Spring House, Pennsylvania, USA","institution_ids":["https://openalex.org/I4405282460"]},{"raw_affiliation_string":"8Department of Biostatistics, Janssen Research & Development, LLC, Spring House, Pennsylvania, USA","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030325032","display_name":"Elizabeth C. Hsia","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]},{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Elizabeth C Hsia","raw_affiliation_strings":["Department of Immunology, Janssen Research & Development, LLC, Spring House, Pennsylvania, USA","University of Pennsylvania Medical School, Philadelphia, PA, USA","10University of Pennsylvania Medical School, Philadelphia, PA, USA","9Department of Immunology, Janssen Research & Development, LLC, Spring House, Pennsylvania, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Immunology, Janssen Research & Development, LLC, Spring House, Pennsylvania, USA","institution_ids":["https://openalex.org/I4405282460"]},{"raw_affiliation_string":"University of Pennsylvania Medical School, Philadelphia, PA, USA","institution_ids":["https://openalex.org/I79576946"]},{"raw_affiliation_string":"10University of Pennsylvania Medical School, Philadelphia, PA, USA","institution_ids":["https://openalex.org/I79576946"]},{"raw_affiliation_string":"9Department of Immunology, Janssen Research & Development, LLC, Spring House, Pennsylvania, USA","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5051248102","display_name":"Mittie K. Doyle","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]},{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mittie K Doyle","raw_affiliation_strings":["Department of Immunology, Janssen Research & Development, LLC, Spring House, Pennsylvania, USA","University of Pennsylvania Medical School, Philadelphia, PA, USA","10University of Pennsylvania Medical School, Philadelphia, PA, USA","9Department of Immunology, Janssen Research & Development, LLC, Spring House, Pennsylvania, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Immunology, Janssen Research & Development, LLC, Spring House, Pennsylvania, USA","institution_ids":["https://openalex.org/I4405282460"]},{"raw_affiliation_string":"University of Pennsylvania Medical School, Philadelphia, PA, USA","institution_ids":["https://openalex.org/I79576946"]},{"raw_affiliation_string":"10University of Pennsylvania Medical School, Philadelphia, PA, USA","institution_ids":["https://openalex.org/I79576946"]},{"raw_affiliation_string":"9Department of Immunology, Janssen Research & Development, LLC, Spring House, Pennsylvania, USA","institution_ids":["https://openalex.org/I4405282460"]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":9,"corresponding_author_ids":["https://openalex.org/A5111657027"],"corresponding_institution_ids":["https://openalex.org/I76134821"],"apc_list":{"value":4870,"currency":"USD","value_usd":4870},"apc_paid":{"value":4870,"currency":"USD","value_usd":4870},"fwci":7.5907,"has_fulltext":true,"cited_by_count":55,"citation_normalized_percentile":{"value":0.97824209,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"71","issue":"10","first_page":"1671","last_page":"1679"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11616","display_name":"Autoimmune and Inflammatory Disorders Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13026","display_name":"Natural Compounds in Disease Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2707","display_name":"Complementary and alternative medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/golimumab","display_name":"golimumab","score":0.9959999918937683},{"id":"https://openalex.org/keywords/rheumatoid-arthritis","display_name":"rheumatoid arthritis","score":0.9950000047683716},{"id":"https://openalex.org/keywords/tnf-alpha-inhibitors","display_name":"TNF-alpha inhibitors","score":0.7820000052452087},{"id":"https://openalex.org/keywords/long-term-treatment","display_name":"long-term treatment","score":0.5260000228881836},{"id":"https://openalex.org/keywords/acr20-response","display_name":"ACR20 response","score":0.7940000295639038},{"id":"https://openalex.org/keywords/severe-infection","display_name":"serious infections","score":0.6150000095367432},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.7009999752044678},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.5099999904632568},{"id":"https://openalex.org/keywords/dose-comparison","display_name":"dose comparison","score":0.40299999713897705},{"id":"https://openalex.org/keywords/subcutaneous-injection","display_name":"subcutaneous injection","score":0.5329999923706055},{"id":"https://openalex.org/keywords/treatment-efficacy-and-safety","display_name":"treatment efficacy and safety","score":0.34200000762939453},{"id":"https://openalex.org/keywords/patient-reported-outcomes","display_name":"patient-reported outcomes","score":0.4399999976158142},{"id":"https://openalex.org/keywords/health-related-quality-of-life","display_name":"health-related quality of life","score":0.6679999828338623},{"id":"https://openalex.org/keywords/patient-satisfaction","display_name":"patient satisfaction","score":0.3440000116825104}],"concepts":[{"id":"https://openalex.org/C2781290027","wikidata":"https://www.wikidata.org/wiki/Q413879","display_name":"Golimumab","level":4,"score":0.9880256652832031},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9546926617622375},{"id":"https://openalex.org/C2777575956","wikidata":"https://www.wikidata.org/wiki/Q187255","display_name":"Rheumatoid arthritis","level":2,"score":0.7797619104385376},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.7420978546142578},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6032812595367432},{"id":"https://openalex.org/C198451711","wikidata":"https://www.wikidata.org/wiki/Q327657","display_name":"Rheumatology","level":2,"score":0.5547733902931213},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5378121137619019},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.4299089312553406},{"id":"https://openalex.org/C204243189","wikidata":"https://www.wikidata.org/wiki/Q1363085","display_name":"Randomization","level":3,"score":0.4211307466030121},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.3951672315597534},{"id":"https://openalex.org/C2777226972","wikidata":"https://www.wikidata.org/wiki/Q415343","display_name":"Etanercept","level":3,"score":0.1708810031414032},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D001172","descriptor_name":"Arthritis, Rheumatoid","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014409","descriptor_name":"Tumor Necrosis Factor-alpha","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D018501","descriptor_name":"Antirheumatic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D018501","descriptor_name":"Antirheumatic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false}],"locations_count":8,"locations":[{"id":"doi:10.1136/annrheumdis-2011-200956","doi":"https://doi.org/10.1136/annrheumdis-2011-200956","is_oa":true,"landing_page_url":"https://doi.org/10.1136/annrheumdis-2011-200956","pdf_url":"https://ard.bmj.com/content/annrheumdis/71/10/1671.full.pdf","source":{"id":"https://openalex.org/S25650217","display_name":"Annals of the Rheumatic Diseases","issn_l":"0003-4967","issn":["0003-4967","1468-2060"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of the Rheumatic Diseases","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:3439650","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/3439650","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Ann Rheum Dis","raw_type":"Text"},{"id":"pmid:22459542","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22459542","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of the rheumatic diseases","raw_type":"Clinical Trial, Phase III"},{"id":"pmh:oai:pure.amsterdamumc.nl:openaire_cris_publications/52a3c081-4bec-44ca-b6df-30fecb435de9","doi":null,"is_oa":false,"landing_page_url":"https://pure.amsterdamumc.nl/en/publications/52a3c081-4bec-44ca-b6df-30fecb435de9","pdf_url":null,"source":{"id":"https://openalex.org/S7407055222","display_name":"Pure Amsterdam UMC","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Smolen, J S, Kay, J, Landew\u00e9, R B M, Matteson, E L, Gaylis, N, Wollenhaupt, J, Murphy, F T, Zhou, Y, Hsia, E C & Doyle, M K 2012, 'Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160', Annals of the rheumatic diseases, vol. 71, no. 10, pp. 1671-1679. https://doi.org/10.1136/annrheumdis-2011-200956","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:escholarship.umassmed.edu:rheumatology_pubs-1100","doi":null,"is_oa":true,"landing_page_url":"https://escholarship.umassmed.edu/rheumatology_pubs/101","pdf_url":null,"source":{"id":"https://openalex.org/S7407064370","display_name":"eScholarship@UMassChan","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Rheumatology Publications","raw_type":"text"},{"id":"pmh:amcpub:oai:pure.amc.nl:publications/1216c716-c213-47f0-9f4d-8139186fd2ad","doi":null,"is_oa":false,"landing_page_url":"https://pure.amc.nl/en/publications/golimumab-in-patients-with-active-rheumatoid-arthritis-who-have-previous-experience-with-tumour-necrosis-factor-inhibitors-results-of-a-longterm-extension-of-the-randomised-doubleblind-placebocontrolled-goafter-study-through-week-160(1216c716-c213-47f0-9f4d-8139186fd2ad).html","pdf_url":null,"source":{"id":"https://openalex.org/S4306401843","display_name":"Data Archiving and Networked Services (DANS)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1322597698","host_organization_name":"Royal Netherlands Academy of Arts and Sciences","host_organization_lineage":["https://openalex.org/I1322597698"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Annals of the rheumatic diseases, 71(10), 1671 - 1679. BMJ Publishing Group","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:open-archive.highwire.org:annrheumdis:71/10/1671","doi":null,"is_oa":false,"landing_page_url":"http://ard.bmj.com/cgi/content/short/71/10/1671","pdf_url":null,"source":{"id":"https://openalex.org/S4406923041","display_name":"HighWire Press Open Archive","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"TEXT"},{"id":"pmh:oai:open-archive.highwire.org:annrheumdis:annrheumdis-2011-200956v1","doi":null,"is_oa":false,"landing_page_url":"http://ard.bmj.com/cgi/content/short/annrheumdis-2011-200956v1","pdf_url":null,"source":{"id":"https://openalex.org/S4406923041","display_name":"HighWire Press Open Archive","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"TEXT"}],"best_oa_location":{"id":"doi:10.1136/annrheumdis-2011-200956","doi":"https://doi.org/10.1136/annrheumdis-2011-200956","is_oa":true,"landing_page_url":"https://doi.org/10.1136/annrheumdis-2011-200956","pdf_url":"https://ard.bmj.com/content/annrheumdis/71/10/1671.full.pdf","source":{"id":"https://openalex.org/S25650217","display_name":"Annals of the Rheumatic Diseases","issn_l":"0003-4967","issn":["0003-4967","1468-2060"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of the Rheumatic Diseases","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.6800000071525574}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320337449","display_name":"Janssen Biotech","ror":"https://ror.org/03qd7mz70"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2109655434.pdf","grobid_xml":"https://content.openalex.org/works/W2109655434.grobid-xml"},"referenced_works_count":29,"referenced_works":["https://openalex.org/W1492940207","https://openalex.org/W1977445011","https://openalex.org/W1984681153","https://openalex.org/W1985004174","https://openalex.org/W1992624913","https://openalex.org/W1994065448","https://openalex.org/W2009928292","https://openalex.org/W2017281030","https://openalex.org/W2018456421","https://openalex.org/W2045789990","https://openalex.org/W2071099746","https://openalex.org/W2073972803","https://openalex.org/W2080464725","https://openalex.org/W2082627748","https://openalex.org/W2099680326","https://openalex.org/W2110177517","https://openalex.org/W2125657144","https://openalex.org/W2127532898","https://openalex.org/W2140965629","https://openalex.org/W2143835145","https://openalex.org/W2152348310","https://openalex.org/W2153405936","https://openalex.org/W2157885750","https://openalex.org/W2159106700","https://openalex.org/W2159728707","https://openalex.org/W4237731780","https://openalex.org/W4249063051","https://openalex.org/W4295125684","https://openalex.org/W4299791636"],"related_works":["https://openalex.org/W2147681024","https://openalex.org/W7000686995","https://openalex.org/W2099046622","https://openalex.org/W2140965629","https://openalex.org/W1988975600","https://openalex.org/W7098051310","https://openalex.org/W1721281419","https://openalex.org/W2118761321","https://openalex.org/W2004369742","https://openalex.org/W1981553585"],"abstract_inverted_index":{"OBJECTIVE:":[0],"The":[1],"aim":[2],"of":[3,35,42,133,159,177,189,300],"this":[4,36],"study":[5,41],"was":[6,307],"to":[7,91,107,150,236,241,248,253,260,265],"assess":[8],"long-term":[9,317],"golimumab":[10,60,66,92,108,114,227,281],"therapy":[11],"in":[12,83,156,173,204,293,298],"patients":[13,104,137,190,224,272,301],"with":[14,80,226,273,309],"rheumatoid":[15],"arthritis":[16],"(RA)":[17],"who":[18,276,302],"discontinued":[19,277],"previous":[20,278],"tumour":[21],"necrosis":[22],"factor":[23],"alpha":[24],"(TNF\u03b1)":[25],"inhibitor(s)":[26],"for":[27,212,243,255,267],"any":[28],"reason.":[29],"METHODS:":[30],"Results":[31],"through":[32,126,144],"week":[33,87,100,127,145,148,151,183],"24":[34,149],"multicentre,":[37],"randomised,":[38],"double-blind,":[39],"placebo-controlled":[40],"active":[43,274],"RA":[44,275],"(\u22654":[45],"tender,":[46],"\u22654":[47],"swollen":[48],"joints)":[49],"were":[50,138,171,233],"previously":[51],"reported.":[52,130],"Patients":[53,74],"received":[54],"placebo":[55],"(Group":[56,61,67],"1),":[57],"50":[58,93,109,228,282],"mg":[59,65,94,116,229,232,285],"2)":[62],"or":[63],"100":[64,96,221,231,284],"3)":[68],"subcutaneous":[69],"injections":[70,286],"every":[71,287],"4":[72,288],"weeks.":[73],"from":[75],"Groups":[76,205],"1":[77,103],"and":[78,95,120,163,175,187,194,197,208,230,238,250,257,262,283,295],"2":[79,112,207],"<20%":[81],"improvement":[82,155,170,201],"tender/swollen":[84],"joints":[85],"at":[86,182],"16":[88],"early":[89],"escaped":[90],"mg,":[97,110],"respectively.":[98,180,210,269],"At":[99],"24,":[101],"Group":[102,111,121],"crossed":[105],"over":[106],"continued":[113,142,303],"50/100":[115],"per":[117,220],"escape":[118],"status":[119],"3":[122],"maintained":[123],"dosing.":[124],"Data":[125],"160":[128],"are":[129],"RESULTS:":[131],"459":[132],"the":[134],"461":[135],"randomised":[136],"treated;":[139],"236/459":[140],"(51%)":[141],"treatment":[143],"160.":[146],"From":[147],"100,":[152],"ACR20":[153,192],"(\u226520%":[154],"American":[157],"College":[158],"Rheumatology":[160],"criteria)":[161],"response":[162,193],"\u22650.25":[164,202],"unit":[165,203],"HAQ":[166,200],"(Health":[167],"Assessment":[168],"Questionnaire)":[169],"sustained":[172,291],"70-73%":[174],"75-81%":[176],"responding":[178],"patients,":[179],"Overall":[181],"160,":[184],"63%,":[185],"67%":[186],"57%":[188],"achieved":[191],"59%,":[195],"65%":[196],"64%":[198],"had":[199],"1,":[206],"3,":[209],"Adjusted":[211],"follow-up":[213],"duration,":[214],"adverse":[215],"event":[216],"incidences":[217],"(95%":[218],"CI)":[219],"patient-years":[222],"among":[223],"treated":[225],"4.70":[234],"(2.63":[235],"7.75)":[237],"8.07":[239],"(6.02":[240],"10.58)":[242],"serious":[244],"infection,":[245],"0.95":[246],"(0.20":[247],"2.77)":[249],"2.04":[251],"(1.09":[252],"3.49)":[254],"malignancy":[256],"0.00":[258],"(0.00":[259],"0.94)":[261],"0.62":[263],"(0.17":[264],"1.59)":[266],"death,":[268],"CONCLUSION:":[270],"In":[271],"TNF-antagonist":[279],"treatment,":[280],"weeks":[289],"yielded":[290],"improvements":[292],"signs/symptoms":[294],"physical":[296],"function":[297],"\u223c57-67%":[299],"treatment.":[304],"Golimumab":[305],"safety":[306,318],"consistent":[308],"other":[310],"anti-TNF":[311],"agents,":[312],"although":[313],"definitive":[314],"conclusions":[315],"regarding":[316],"require":[319],"further":[320],"monitoring.":[321]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":6},{"year":2015,"cited_by_count":6},{"year":2014,"cited_by_count":9},{"year":2013,"cited_by_count":13},{"year":2012,"cited_by_count":3}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}